Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma.

De Re V, Tornesello ML, De Zorzi M, Caggiari L, Pezzuto F, Leone P, Racanelli V, Lauletta G, Gragnani L, Buonadonna A, Vaccher E, Zignego AL, Steffan A, Buonaguro FM.

Front Microbiol. 2019 Mar 15;10:475. doi: 10.3389/fmicb.2019.00475. eCollection 2019.

2.

Cancer Diagnostic and Predictive Biomarkers 2018.

Buonaguro FM, Caposio P, Tornesello ML, De Re V, Franco R.

Biomed Res Int. 2019 Jan 8;2019:3879015. doi: 10.1155/2019/3879015. eCollection 2019. No abstract available.

3.

Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients.

Petrizzo A, Tagliamonte M, Mauriello A, Costa V, Aprile M, Esposito R, Caporale A, Luciano A, Arra C, Tornesello ML, Buonaguro FM, Buonaguro L.

J Transl Med. 2018 Oct 19;16(1):286. doi: 10.1186/s12967-018-1662-9.

4.

Potentiating cancer vaccine efficacy in liver cancer.

Tagliamonte M, Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Buonaguro L.

Oncoimmunology. 2018 Jul 23;7(10):e1488564. doi: 10.1080/2162402X.2018.1488564. eCollection 2018.

5.

Prevalence of "unclassified" HPV genotypes among women with abnormal cytology.

Annunziata C, Stellato G, Greggi S, Sanna V, Curcio MP, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2018 Jul 24;13:26. doi: 10.1186/s13027-018-0199-0. eCollection 2018.

6.

The Role of Sensing Peptides in the Cross-talk between Microbiota and Human Cancer Cells.

Tornesello AL, Buonaguro L, Tornesello ML, Buonaguro FM.

Mini Rev Med Chem. 2018;18(18):1567-1571. doi: 10.2174/1389557518666180713112119. Review.

PMID:
30003859
7.

Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers.

Tornesello ML, Annunziata C, Tornesello AL, Buonaguro L, Buonaguro FM.

Cancers (Basel). 2018 Jun 22;10(7). pii: E213. doi: 10.3390/cancers10070213. Review.

8.

Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.

Annunziata C, Pezzuto F, Greggi S, Ionna F, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Int J Cancer. 2018 Sep 1;143(5):1153-1161. doi: 10.1002/ijc.31412. Epub 2018 Apr 17.

9.

Cellular prognostic markers in hepatitis-related hepatocellular carcinoma.

Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Tagliamonte M, Buonaguro L.

Infect Agent Cancer. 2018 Mar 27;13:10. doi: 10.1186/s13027-018-0183-8. eCollection 2018. Review.

10.

The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma.

Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML.

Int J Mol Sci. 2018 Mar 28;19(4). pii: E1007. doi: 10.3390/ijms19041007. Review.

11.

Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia.

Starita N, Buonaguro L, Buonaguro FM, Tornesello ML.

J Transl Med. 2018 Mar 21;16(1):77. doi: 10.1186/s12967-018-1456-0.

12.

Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting.

Petrizzo A, Mauriello A, Luciano A, Rea D, Barbieri A, Arra C, Maiolino P, Tornesello M, Gigantino V, Botti G, Ciliberto G, Buonaguro FM, Tagliamonte M, Buonaguro L.

Oncotarget. 2017 Dec 8;9(3):3576-3589. doi: 10.18632/oncotarget.23181. eCollection 2018 Jan 9.

13.

Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.

Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, Mancini A.

Redox Biol. 2018 May;15:467-479. doi: 10.1016/j.redox.2018.01.009. Epub 2018 Feb 3. Review.

14.

Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents.

Borrelli A, Tornesello AL, Tornesello ML, Buonaguro FM.

Molecules. 2018 Jan 31;23(2). pii: E295. doi: 10.3390/molecules23020295. Review.

15.

New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology.

Tornesello AL, Buonaguro L, Tornesello ML, Buonaguro FM.

Molecules. 2017 Aug 2;22(8). pii: E1282. doi: 10.3390/molecules22081282. Review.

16.

Cancer Diagnostic and Predictive Biomarkers 2016.

Buonaguro FM, Pauza CD, Tornesello ML, Hainaut P, Franco R, Tommasino M.

Biomed Res Int. 2017;2017:7362721. doi: 10.1155/2017/7362721. Epub 2017 Jun 18. No abstract available.

17.

Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma.

Starita N, Di Monta G, Cerasuolo A, Marone U, Anniciello AM, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2017 Jun 19;12:35. doi: 10.1186/s13027-017-0147-4. eCollection 2017.

18.

Use of adjuvants for immunotherapy.

Circelli L, Tornesello M, Buonaguro FM, Buonaguro L.

Hum Vaccin Immunother. 2017 Aug 3;13(8):1774-1777. doi: 10.1080/21645515.2017.1321725. Epub 2017 Jun 12.

19.

Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma.

Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2017 May 19;12:27. doi: 10.1186/s13027-017-0138-5. eCollection 2017. Review.

20.

Comparative analysis of HPV16 gene expression profiles in cervical and in oropharyngeal squamous cell carcinoma.

Cerasuolo A, Annunziata C, Tortora M, Starita N, Stellato G, Greggi S, Maglione MG, Ionna F, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Oncotarget. 2017 May 23;8(21):34070-34081. doi: 10.18632/oncotarget.15977.

21.

An Engineered Cell-Instructive Stroma for the Fabrication of a Novel Full Thickness Human Cervix Equivalent In Vitro.

De Gregorio V, Imparato G, Urciuolo F, Tornesello ML, Annunziata C, Buonaguro FM, Netti PA.

Adv Healthc Mater. 2017 Jun;6(11). doi: 10.1002/adhm.201601199. Epub 2017 Mar 29.

PMID:
28371541
22.

An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases.

Tornesello AL, Tornesello ML, Buonaguro FM.

Mini Rev Med Chem. 2017;17(9):758-770. doi: 10.2174/1389557517666170120151739. Review.

PMID:
28117023
23.

MDM2 gene polymorphisms and risk of classic Kaposi's sarcoma among Iranian patients.

Varmazyar S, Marashi SM, Shoja Z, Tornesello ML, Buonaguro FM, Shahmahmoodi S, Safaie-Naraghi Z, Jalilvand S.

Med Microbiol Immunol. 2017 Apr;206(2):157-163. doi: 10.1007/s00430-016-0491-9. Epub 2017 Jan 12.

PMID:
28083704
24.

Immunological effects of a novel RNA-based adjuvant in liver cancer patients.

Circelli L, Petrizzo A, Tagliamonte M, Heidenreich R, Tornesello ML, Buonaguro FM, Buonaguro L.

Cancer Immunol Immunother. 2017 Jan;66(1):103-112. doi: 10.1007/s00262-016-1923-5. Epub 2016 Nov 10.

PMID:
27832318
25.

HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2.

De Re V, De Zorzi M, Caggiari L, Lauletta G, Tornesello ML, Fognani E, Miorin M, Racanelli V, Quartuccio L, Gragnani L, Russi S, Pavone F, Ghersetti M, Costa EG, Casarin P, Bomben R, Mazzaro C, Basaglia G, Berretta M, Vaccher E, Izzo F, Buonaguro FM, De Vita S, Zignego AL, De Paoli P, Dolcetti R.

Oncotarget. 2016 Jun 21;7(25):37487-37497. doi: 10.18632/oncotarget.9303.

26.

Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery.

Petrizzo A, Caruso FP, Tagliamonte M, Tornesello ML, Ceccarelli M, Costa V, Aprile M, Esposito R, Ciliberto G, Buonaguro FM, Buonaguro L.

Sci Rep. 2016 Jul 8;6:29258. doi: 10.1038/srep29258.

27.

Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.

Pezzuto F, Izzo F, Buonaguro L, Annunziata C, Tatangelo F, Botti G, Buonaguro FM, Tornesello ML.

Oncotarget. 2016 Aug 23;7(34):54253-54262. doi: 10.18632/oncotarget.9801.

28.

Solid Phase Formylation of N-Terminus Peptides.

Tornesello AL, Sanseverino M, Buonaguro FM.

Molecules. 2016 Jun 4;21(6). pii: E736. doi: 10.3390/molecules21060736.

29.

Detection of human papillomavirus DNA in peri-tumor tissues and pelvic lymph nodes as potential molecular marker of micrometastasis in cervical cancer.

Tortora M, Annunziata C, Liguori G, Losito S, Botti G, Greggi S, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2016 May 11;11:22. doi: 10.1186/s13027-016-0068-7. eCollection 2016.

30.

Candidate Soluble Immune Mediators in Young Women with High-Risk Human Papillomavirus Infection: High Expression of Chemokines Promoting Angiogenesis and Cell Proliferation.

Zanotta N, Tornesello ML, Annunziata C, Stellato G, Buonaguro FM, Comar M.

PLoS One. 2016 Mar 18;11(3):e0151851. doi: 10.1371/journal.pone.0151851. eCollection 2016.

31.

Cancer vaccines for hepatocellular carcinoma: future directions.

Buonaguro FM, Buonaguro L.

Immunotherapy. 2016;8(4):391-3. doi: 10.2217/imt-2015-0018. No abstract available.

PMID:
26973120
32.

Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections.

Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM.

Oncotarget. 2016 May 3;7(18):25087-102. doi: 10.18632/oncotarget.7837. Review.

33.

A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice.

Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Rea D, Barbieri A, Arra C, Maiolino P, Tornesello M, Ciliberto G, Buonaguro FM, Buonaguro L.

J Transl Med. 2016 Feb 24;14:58. doi: 10.1186/s12967-016-0812-1.

34.

Combinatorial immunotherapy strategies for hepatocellular carcinoma.

Tagliamonte M, Petrizzo A, Tornesello ML, Ciliberto G, Buonaguro FM, Buonaguro L.

Curr Opin Immunol. 2016 Apr;39:103-13. doi: 10.1016/j.coi.2016.01.005. Epub 2016 Feb 4. Review.

PMID:
26851637
35.

Cancer Diagnostic and Predictive Biomarkers 2015.

Buonaguro FM, Pauza CD, Tornesello ML, Hainaut P, Franco R.

Biomed Res Int. 2015;2015:235985. doi: 10.1155/2015/235985. Epub 2015 Oct 12. No abstract available.

36.

Identification of Human Herpesvirus 8 Sequences in Conjunctiva Intraepithelial Neoplasia and Squamous Cell Carcinoma of Ugandan Patients.

Starita N, Annunziata C, Waddell KM, Buonaguro L, Buonaguro FM, Tornesello ML.

Biomed Res Int. 2015;2015:801353. doi: 10.1155/2015/801353. Epub 2015 Oct 5. Review.

37.

Functional characterization of biodegradable nanoparticles as antigen delivery system.

Petrizzo A, Conte C, Tagliamonte M, Napolitano M, Bifulco K, Carriero V, De Stradis A, Tornesello ML, Buonaguro FM, Quaglia F, Buonaguro L.

J Exp Clin Cancer Res. 2015 Oct 6;34:114. doi: 10.1186/s13046-015-0231-9.

38.

Systems Biology Approach for Cancer Vaccine Development and Evaluation.

Circelli L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L.

Vaccines (Basel). 2015 Jul 14;3(3):544-55. doi: 10.3390/vaccines3030544. Review.

39.

Impairment of T cell development and acute inflammatory response in HIV-1 Tat transgenic mice.

Fiume G, Scialdone A, Albano F, Rossi A, Tuccillo FM, Rea D, Palmieri C, Caiazzo E, Cicala C, Bellevicine C, Falcone C, Vecchio E, Pisano A, Ceglia S, Mimmi S, Iaccino E, de Laurentiis A, Pontoriero M, Agosti V, Troncone G, Mignogna C, Palma G, Arra C, Mallardo M, Buonaguro FM, Scala G, Quinto I.

Sci Rep. 2015 Sep 7;5:13864. doi: 10.1038/srep13864.

40.

An overview of new biomolecular pathways in pathogen-related cancers.

Tornesello ML, Buonaguro L, Buonaguro FM.

Future Oncol. 2015;11(11):1625-39. doi: 10.2217/fon.15.87. Review.

PMID:
26043216
41.

Cellular prognostic markers in hepatocellular carcinoma.

Buonaguro L, Tagliamonte M, Petrizzo A, Damiano E, Tornesello ML, Buonaguro FM.

Future Oncol. 2015;11(11):1591-8. doi: 10.2217/fon.15.39. Review.

PMID:
26043213
42.

Foreword. Cancer biomarkers.

Buonaguro FM, Tornesello ML, Buonaguro L.

Future Oncol. 2015;11(11):1585-6. doi: 10.2217/fon.15.74. No abstract available.

43.

Correction: Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases.

De Re V, Caggiari L, De Zorzi M, Repetto O, Zignego AL, Izzo F, Tornesello ML, Buonaguro FM, Mangia A, Sansonno D, Racanelli V, De Vita S, Pioltelli P, Vaccher E, Beretta M, Mazzaro C, Libra M, Gini A, Zucchetto A, Cannizzaro R, De Paoli P.

PLoS One. 2015 May 15;10(5):e0128849. doi: 10.1371/journal.pone.0128849. eCollection 2015. No abstract available.

44.

Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies.

Pezzuto F, Buonaguro L, Caponigro F, Ionna F, Starita N, Annunziata C, Buonaguro FM, Tornesello ML.

Oncology. 2015;89(3):125-36. doi: 10.1159/000381717. Epub 2015 May 8. Review.

PMID:
25967534
45.

Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model.

Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Arra C, Maiolino P, Izzo F, Tornesello ML, Aurisicchio L, Ciliberto G, Buonaguro FM, Buonaguro L.

Cancer Immunol Immunother. 2015 Oct;64(10):1305-14. doi: 10.1007/s00262-015-1698-0. Epub 2015 May 6.

PMID:
25944003
46.

Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.

De Re V, Caggiari L, De Zorzi M, Repetto O, Zignego AL, Izzo F, Tornesello ML, Buonaguro FM, Mangia A, Sansonno D, Racanelli V, De Vita S, Pioltelli P, Vaccher E, Berretta M, Mazzaro C, Libra M, Gini A, Zucchetto A, Cannizzaro R, De Paoli P.

PLoS One. 2015 Feb 20;10(2):e0117420. doi: 10.1371/journal.pone.0117420. eCollection 2015. Erratum in: PLoS One. 2015;10(5):e0128849. Beretta, Massimiliano [corrected to Berretta, Massimiliano].

47.

Burkitt lymphoma research in East Africa: highlights from the 9(th) African organization for research and training in cancer conference held in Durban, South Africa in 2013.

Simbiri KO, Biddle J, Kinyera T, Were PA, Tenge C, Kawira E, Masalu N, Sumba PO, Lawler-Heavner J, Stefan CD, Buonaguro FM, Robinson D, Newton R, Harford J, Bhatia K, Mbulaiteye SM.

Infect Agent Cancer. 2014 Sep 11;9:32. doi: 10.1186/1750-9378-9-32. eCollection 2014.

48.

The XIX century smallpox prevention in Naples and the risk of transmission of human blood-related pathogens.

Buonaguro FM, Tornesello ML, Buonaguro L.

J Transl Med. 2015 Jan 27;13:33. doi: 10.1186/s12967-015-0400-9.

49.

Antigen-specific vaccines for cancer treatment.

Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, Buonaguro L.

Hum Vaccin Immunother. 2014;10(11):3332-46. doi: 10.4161/21645515.2014.973317. Review.

50.

TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.

Tornesello ML, Annunziata C, Buonaguro L, Losito S, Greggi S, Buonaguro FM.

J Transl Med. 2014 Sep 16;12:255. doi: 10.1186/s12967-014-0255-5.

Supplemental Content

Loading ...
Support Center